中国药科大学学报2017，Vol.48Issue(6)：629-634,6.DOI:10.11665/j.issn.1000-5048.20170601
临床代谢组学及其在冠心病诊疗中的研究进展
Clinical metabolomics in diagnosis and therapy of coronary artery disease
摘要
Abstract
Metabolomics,a hot field of research of life science in recent years,is to analyze endogenous smallmolecule metabolites in biological samples for an overall understanding of the characteristics of metabolic disorders.A growing number of studies have confirmed the application of metabolomics for clinical diagnosis and treatment of diseases."Metabolic fingerprint" of biological fluids can be employed for disease prevention,timely diagnosis,accurate treatment,prognostic assessment and drug discovery.Clinical metabolomics is to measure low-molecule-weight metabolites' alterations of individuals in response to physiological stressors,disease processes,or drug therapy,aiming to discover potential biomarkers and drug targets.Coronary artery disease (CAD) is characterized as complex molecular events.Metabolic disturbances are involved in CAD progression.The application of metabolomics to CAD is an emerging field.Advances in metabolomics improve our knowledge on CAD in early diagnosis,prognostic prediction,and personalized therapy.关键词
临床代谢组学/冠心病/代谢标志物/进展Key words
clinical metabolomics/coronary arterydisease/metabolic biomarkers/advances分类
医药卫生引用本文复制引用
殷锟鹏,郑好,谢滨新,李萍,张蕾,范勇,朱伟,齐炼文..临床代谢组学及其在冠心病诊疗中的研究进展[J].中国药科大学学报,2017,48(6):629-634,6.基金项目
国家自然科学基金资助项目(No.91639115)This study was supported by the Natural Science Foundation of China(No.91639115) （No.91639115）
